Jianfeng Group won "Jinhua Charity Award"
Release time:
2023-07-11
"
Jinhua Charity Award" is determined on the basis of various social recommendations and self-recommendation, recommended by the county (city, district), reviewed by the selection committee and soliciting opinions from relevant departments. There are six categories of awards, including charity model awards, individual donation awards, institutional donation awards, and voluntary service awards. 20 units including Jianfeng have won institutional donation awards. For more than 5 years, Jianfeng has been pursuing the corporate philosophy of "taking from the society and contributing to the society" and "reaching the world", and actively practicing social responsibilities. The social welfare undertakings it has participated in have covered poverty alleviation, anti-epidemic, and medical care., Disaster relief, education, culture and other fields, the value of donations and materials has been nearly 14 million yuan in the past three years. In addition, in the special campaign of "thousands of enterprises unite thousands of villages and eliminate weak villages", peak subordinate enterprises have paired up with seven weak collective economic villages in Jinhua, Daye, Pu'er and other places. In addition to investing 0.85 billion yuan to build a cement base in Gulong Town, a state-level extremely poor town in Huangping County, Guizhou Province, it also led the lead and organized Jinhua entrepreneurs to visit Huangping, Pu'er, Sichuan and other places for investigation and negotiation, to build a bridge to strengthen the cooperation between the east and the west; as the chairman (chairman) unit of the Municipal Federation of Industry and Commerce, actively respond to the "Special Action of Zhejiang Merchants to Help the Leap-forward Development of 26 Counties in Mountainous Areas" initiated by the Provincial Federation of Industry and Commerce, organize and lead a group of well-known entrepreneurs to enter Wuyi, Pan'an, carry out exchanges and cooperation, and contribute to driving the leap-forward development of 26 counties in mountainous areas.
Prior to this, the company has also won the Jinhua City "Charity Honor Unit", Jinhua City "Advanced Unit of Free Blood Donation" and other charitable awards. (Group Union)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31